Adding carfilzomib to lenalidomide and dexamethasone resulted in a higher PFS and better overall quality of life for relapsed multiple myeloma patients.
Hematologic Cancer Targets
T-lymphoblastic leukemia (T-ALL) should no longer be considered a poor-risk disease in the pediatric population, according to data presented at ASH.
Sorafenib proved to have a high level of efficacy in younger acute myeloid leukemia patients, improving both event- and relapse-free survival over placebo.
The FDA has approved blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia.
Ahead of the 2014 ASH Annual Meeting & Exhibition we discuss current treatment strategies for elderly patients with acute myeloid leukemia.
Early trial data support further evaluation of ixazomib combined with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Non-germinal center B-cell-like DLBCL patients derived the most benefit from treatment with the immunochemotherapy regimen R-ACVBP compared with R-CHOP.
Adding the HDAC inhibitor valproic acid to decitabine did not improve outcomes in patients with myelodysplastic syndromes or acute myeloid leukemia.
Patients who experienced early relapse of multiple myeloma after undergoing autologous stem cell transplantation had worse progression-free and overall survival.
In this interview we discuss the use of newly approved agents for chronic lymphocytic leukemia, next-generation therapies in the pipeline, and how the treatment of this type of leukemia has changed.